标准球囊血管成形术与药物涂层球囊单独或联合激光准分子斑块旋切术治疗股腘动脉支架内再狭窄的初始结果及对比分析(INTACT)
INTACT 多中心前瞻性三臂随机试验纳入 134 例 Rutherford 2-5 级、支架内再狭窄≥70% 的患者,比较单纯经皮腔内血管成形术(PTA)、PTA+药物涂层球囊(DCB)、PTA+准分子激光斑块旋切(ELA)+DCB 的疗效与安全性,随访 18 个月。结果显示 PTA+ELA+DCB 和 PTA+DCB 较单纯 PTA 降低复发性支架内再狭窄>70% 并提高一期通畅率,但 PTA+DCB 组无主要不良事件生存率低于单纯 PTA 组。
要点
- PTA+ELA+DCB 组复发性 ISR>70% 为 30.0%(p=.04),PTA+DCB 组为 30.2%(p=.05),均低于单纯 PTA 组的 51.2%。
- 12 个月一期通畅率 PTA+ELA+DCB 组 78.7%、PTA+DCB 组 70.4%,均高于单纯 PTA 组的 61.5%(log-rank p=.04 和 p=.02)。
- 18 个月一期通畅率 PTA+ELA+DCB 组 61.6%、PTA+DCB 组 67.7%,均高于单纯 PTA 组的 37.3%。
核心结论
- PTA+ELA+DCB 和 PTA+DCB 较单纯 PTA 降低复发性 ISR>70% 并提高 18 个月一期通畅率,未显示 MAE 增加但可能把握度不足。
研究设计与样本
- INTACT 为多中心、前瞻性、三臂随机对照试验,2015 年 12 月至 2019 年 11 月在 14 个中心开展。
- 纳入 Rutherford 2-5 级、ISR≥70% 的患者,随访 18 个月。
- 134 例受试者随机分为单纯 PTA 组(n=41)、PTA+DCB 组(n=43)、PTA+ELA+DCB 组(n=50)。
- 主要疗效终点为双功超声分析的复发性 ISR>70%,主要安全终点为主要不良事件(MAE),定义为死亡、大截肢或靶病变血运重建(TLR)。
主要发现
- 手术成功率三组相似(p=.74),临床成功率亦相似(p=.17)。
- 复发性 ISR>70%:PTA+ELA+DCB 组 30.0%(p=.04)、PTA+DCB 组 30.2%(p=.05),单纯 PTA 组 51.2%。
- 12 个月一期通畅率:PTA+ELA+DCB 组 78.7%(log-rank p=.04)、PTA+DCB 组 70.4%(log-rank p=.02),单纯 PTA 组 61.5%。
- 18 个月一期通畅率:PTA+ELA+DCB 组 61.6%、PTA+DCB 组 67.7%,单纯 PTA 组 37.3%。
- 无 MAE 生存率:PTA+DCB 组 27.9% 低于单纯 PTA 组 53.7%(p=.02),PTA+ELA+DCB 组 40.0% 与单纯 PTA 组无差异;主要由 TLR 驱动,PTA+ELA+DCB 组发生 2 例大截肢(4.0%,p=.18)。
局限性
- 原文结论指出未显示 MAE 增加但可能把握度不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite improved patency with newer-generation nitinol stents, one-half of patients will require secondary interventions for in-stent restenosis (ISR). The best treatment strategy remains unclear. This study aimed to compare drug-coated balloons (DCBs) used alone or in association with excimer laser atherectomy (ELA) to simple percutaneous transluminal angioplasty (PTA) in the treatment of femoropopliteal-ISR. METHODS: The INTACT trial is a multicenter, prospective, triple-arm randomized trial conducted across 14 centers from December 2015 to November 2019. Patients Rutherford Class 2-5 with ISR≥70% were followed-up for 18 months. The primary efficacy endpoint was recurrent ISR>70% by duplex ultrasound analysis. The primary safety endpoint was major adverse events (MAEs) defined as death, major amputation, or target lesion revascularization (TLR). RESULTS: Around 134 subjects were randomized to PTA alone (n=41), PTA+DCB (n=43) or PTA+ELA+DCB (n=50). Procedural success was similar (p=.74), as was clinical success (p=.17). The number of recurrent ISR>70% decreased after PTA+ELA+DCB (30.0%; p=.04) and PTA+DCB (30.2%; p=.05) compared to PTA alone (51.2%). Primary patency was higher after PTA+ELA+DCB (log-rank p=.04) and PTA+DCB (log-rank p=.02) compared to PTA alone at 12 months (78.7% and 70.4% vs 61.5%) and 18 months (61.6% and 67.7% vs 37.3%). Freedom from MAEs was lower after PTA+DCB (27.9%) compared to PTA alone (53.7%; p=.02) but did not differ with PTA+ELA+DCB (40.0%). It was primarily driven by TLR; 2 major amputations occurred after PTA+ELA+DCB (4.0%; p=.18). CONCLUSION: This independent study demonstrated a decrease in recurrent ISR>70% and increase in primary patency up to 18 months after PTA+ELA+DCB and PTA+DCB compared to PTA alone in the treatment of FP-ISR. It did not show an increase in MAEs but could have lacked power.Clinical ImpactThis multicenter, prospective, triple-arm randomized, controlled trial focuses on the results of adjunctive therapies, such as excimer laser atherectomy (ELA) and/or drug-coated balloons (DCBs) in the treatment of in-stent restenosis (ISR) in femoropopliteal lesions in 134 patients. It has the originality of being an independent study funded by a grant from the French Ministry of Health. This study confirms a significant decrease in recurrent ISR >70% and increase in primary patency up to 18 months after the use of ELA+DCB and DCBs compared to simple percutaneous transluminal angioplasty in the treatment of femoropopliteal ISR without an increase in major adverse events.
引用
- Ducasse E, Sapoval M, Brunet J, et al. Outcomes and Comparative Analysis of the Initial Results of Standard Balloon Angioplasty Versus Drug-Coated Balloons Alone Versus in Association With Laser-Excimer Atherectomy in the Treatment of Femoropopliteal Artery In-Stent Restenosis (INTACT). J Endovasc Ther. 2024. PMID: 38659343. doi:10.1177/15266028241248333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。